KBC Group’s Ascendis Pharma A/S ASND Stock Holding History

KBC Group’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$74K	Sell	278 -78	-22%	-$18.2K	﹤0.01%	1566
2026 Q1	$81K	Hold	356	–	–	﹤0.01%	1445
2025 Q4	$76K	Hold	356	–	–	﹤0.01%	1457
2025 Q3	$71K	Hold	356	–	–	﹤0.01%	1478
2025 Q2	$61K	Sell	356 -55	-13%	-$8.96K	﹤0.01%	1492
2025 Q1	$64K	Hold	411	–	–	﹤0.01%	1712
2024 Q4	$57K	Hold	411	–	–	﹤0.01%	1789
2024 Q3	$61K	Buy	+411	New	+$55.5K	﹤0.01%	1618

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

KBC Group's ASND Position: Q2 2026 in Review

KBC Group reduced its Ascendis Pharma A/S (ASND) stake by 22% in Q2 2026, selling an estimated $18.2K and leaving 278 shares worth $74K. The position accounts for ﹤0.01% of the portfolio, ranked #1566.

KBC Group first reported a position in ASND in Q3 2024 and has held it in 8 quarters since. The position peaked at $81K in Q1 2026. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

KBC Group held 278 shares of Ascendis Pharma A/S worth $74K as of Q2 2026.
KBC Group sold 78 Ascendis Pharma A/S shares in Q2 2026, an estimated $18.2K.
Ascendis Pharma A/S made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1566 holding.
KBC Group first reported a position in Ascendis Pharma A/S in Q3 2024 and has held it in 8 quarters since.
KBC Group's Ascendis Pharma A/S position peaked at $81K in Q1 2026.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.